IGC Pharma, Inc. announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models. Plaques are a key hallmark and therapeutic target of Alzheimer's disease.

TGR-63 is a patent pending molecule designed to disrupt the structure of the amyloid beta ("Aß") peptide, one of the key hallmarks of Alzheimer's. TGR-63 targets plaques by addressing the misfolding and aggregation of amyloid-ß peptides, specifically the toxic Aß42 aggregation species associated with neuronal toxicity and cognitive decline. Preclinical investigations also indicate a recovery of behavioral functions in an animal model of Alzheimer's, suggesting that TGR-63 could possibly be used as a treatment for anxiety in human Alzheimer's. The preclinical trial was conducted on APP/PS1 (transgenic) mice that are genetically modified to carry mutations of the Amyloid Precursor Protein (APP) gene that lead to the production of a specific form of Aß peptide, a key component of amyloid plaque in the brains of individuals with Alzheimer's. During the investigation, two groups of APP/PS1 mice undertook an Open-Field ("OF") test, a behavioral assessment designed to measure anxiety-like behavior, stress and coping responses, and emotional state, among others, in rodent models. The mice in the APP/PS1 group that received TGR-63 treatment showed significant improvements in their emotional well-being and anxiety levels compared to the group that didn't receive treatment.

A series of tests were used to measure these improvements. First, in the Open-Field (OF) test, the treated mice displayed a 43% reduction in their overall movement within the test area, which was highly statistically significant (p<0.0001). They also showed a 59% reduction in movement within the central zone of the test area (p<0.01).

Additionally, in a more specialized analysis called the Center Zone Exploration (CZE) Analysis, the TGR-63 treated group exhibited a 55% improvement compared to the untreated group (p<0.05). The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in Alzheimer's mouse model, reinforcing its potential as a promising treatment.